Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hill Democrats Continue Inquiries Into High Prices For New Versions Of Old Drugs; Avanir's Nuedexta And URL Pharma's Colcrys Targeted

This article was originally published in The Pink Sheet Daily

Executive Summary

Letters from Sen. Kohl and Reps. Waxman, Pallone and DeGette are reminiscent of the recent uproar over pricing for KV's Makena.
Advertisement

Related Content

With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
Colcrys Promo Eats Pavement As FDA Objects To Ad Of Motorcyclist Holding Teacup
Pharma Industry Pushes A Broadened Meaning For “Orphan”
Avanir Relying On PBA Drug Nuedexta For Success
KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
The Winning Combination: Avanir’s Nuedexta Finally Cleared For Emotional Incontinence

Topics

Advertisement
UsernamePublicRestriction

Register

PS072286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel